(Bethesda, Md.) -- The Ensuring Access to Clinical Trials Act (EACT) -- introduced by Senators Ron Wyden (D-OR), Orrin G. Hatch (R-UT), Edward J. Markey (D-MA), and Sherrod Brown (D-OH) and co-sponsored by an additional 12 senators -- passed a vote by the Senate this evening. The EACT was drafted to make the Improving Access to Clinical Trials Act (IACT) of 2009 permanent, which is set to expire in October 2015.
The IACT allows individuals living with rare diseases, such as cystic fibrosis, to participate in clinical trials without losing access to government benefits including Supplemental Security Income (SSI) and
The CF Foundation championed the original IACT legislation and has actively supported the Ensuring Access to Clinical Trials Act in 2015.
“We applaud the United States Senate for passing this critical legislation, which will help advance
The Ensuring Access to Clinical Trials Act will now be referred to the House of Representatives for consideration.
About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more cystic fibrosis research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a